|Bid||1,891.00 x 128000|
|Ask||1,895.00 x 209400|
|Day's Range||1,889.00 - 1,989.00|
|52 Week Range||834.60 - 2,290.00|
|Beta (5Y Monthly)||2.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 31, 2021 - Jun 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT 2020 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced its 2020 financial and operational results in a March 30, 2021 press release and filing of Form 10-K . The reports were followed by a conference call that morning which discussed recent achievements including results from clinical trials,
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2020 and provided a business update on recent corporate and clinical developments.
NEW YORK, NY / ACCESSWIRE / March 30, 2021 / Protalix Biotherapeutics, Inc. (AMEX:PLX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 30, 2021 at 8:30 AM Eastern Time.